Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2025
Advertising and consultation-practice scrutiny
Australian and UK commentary examined Juniper's promotional practices and whether online weight-loss injections could be accessed through questionnaire-based processes without adequate real-time clinical consultation.
2024
Scrutiny of compounded GLP-1 prescribing
Juniper was included in wider scrutiny of telehealth prescribing and pharmacy-compounded GLP-1 products, whose regulatory approval, quality assurance and adverse-event reporting can differ from approved commercial medicines.
2023
Investigation into Ozempic-related communications
The Australian TGA investigated whether Juniper emails discussing Ozempic availability indirectly advertised a prescription-only medicine.